spacer
home > ebr > summer 2003 > are patents the beating heart of your boardroom?
PUBLICATIONS
European Biopharmaceutical Review

Are Patents the Beating Heart of your Boardroom?

Most companies do not yet understand that intellectual property (IP) is a lifeline in the brutally competitive world we now face. If you don't believe me here is a quick and easy way to determine the level of IP knowledge in your organisation.

Ask around your colleagues, or even better your boardroom, this simple question: how many years can a court enforce your patents, copyright and trademarks upon other companies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ian Harvey, Chief Executive Officer of BTG plc and Chairman of the Government's Intellectual Property Advisory Committee

Ian Harvey is the CEO of BTG, a global technology commercialisation company. He is also Chairman of both the Intellectual Property Institute and the DTI's Intellectual Property Advisory Committee. He joined BTG in 1985 as Chief Executive having spent 10 years with Vickers and Laporte Industries and seven years with the World Bank. Between 1988 and 1993 he served as a member of the Prime Minister's Advisory Council on Science and Technology.

Ian is a Fellow of Nottingham University (1994), and a Member of the Advisory Panel for Science and Technology Policy Research of Sussex University (SPRU) since 1989. He has an MA in Mechanical Sciences from Cambridge University and an MBA from Harvard University.

spacer
Ian Harvey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement